SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipient

Trial Profile

SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipient

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Brincidofovir (Primary) ; Valganciclovir
  • Indications Cytomegalovirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms BCV CMV vGCV; SUSTAIN
  • Sponsors Chimerix
  • Most Recent Events

    • 20 Feb 2016 According to a Chimerix media release, status changed from active, no longer recruiting to discontinued.
    • 20 Feb 2016 According to a Chimerix media release, the company has elected to close the Phase 3 SUSTAIN and SURPASS trials based on review of data from SUPPRESS trial.
    • 11 Jan 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top